Skip to main content
Erschienen in: Die Innere Medizin 2/2020

03.02.2020 | Cholangiokarzinom | Schwerpunkt: Lebertumoren

Chirurgische Therapie bei Lebertumoren – Leberresektion und -transplantation

verfasst von: Prof. Dr. H. Lang, MA, MD, FACS, S. Heinrich, F. Bartsch, F. Hüttl, J. Baumgart, J. Mittler

Erschienen in: Die Innere Medizin | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die häufigsten primären malignen Lebertumoren sind das hepatozelluläre Karzinom (HCC) und das intrahepatische cholangiozelluläre Karzinom („intrahepatic cholangiocellular adenocarcinoma“ [iCCA]). Beim HCC in Zirrhose bietet die Lebertransplantation durch die vollständige Hepatektomie neben der größeren chirurgischen Radikalität auch den Vorteil der Entfernung des präkanzerotischen Zirrhosegewebes. Beim HCC in nichtzirrhotischer Leber stellt ebenso wie beim iCCA die Leberresektion die Behandlung der Wahl dar. Heutzutage können in erfahrenen Zentren auch ausgedehnte Leberresektionen mit einer überschaubaren Mortalität durchgeführt werden. Dabei sollte die chirurgische Behandlungsentscheidung in multimodale Konzepte eingebettet sein und im Rahmen interdisziplinärer Tumorkonferenzen mit entsprechender Expertise auf allen Gebieten erfolgen.
Literatur
1.
Zurück zum Zitat Agopian VG, Harlander-Locke MP, Ruiz RM et al (2017) Impact of pretransplant bridging locoregional therapy for patients with hepatocellular carcinoma within Milan Criteria undergoing liver transplantation: Analysis of 3601 patients from the US multicenter HCC transplant consortium. Ann Surg 266:525–535PubMed Agopian VG, Harlander-Locke MP, Ruiz RM et al (2017) Impact of pretransplant bridging locoregional therapy for patients with hepatocellular carcinoma within Milan Criteria undergoing liver transplantation: Analysis of 3601 patients from the US multicenter HCC transplant consortium. Ann Surg 266:525–535PubMed
2.
Zurück zum Zitat Akateh C, Black SA, Conteh L et al (2019) Neoadjuvant and adjuvant strategies for hepatocellular carcinoma. World J Gastroenterol 25:3704–3721PubMedPubMedCentral Akateh C, Black SA, Conteh L et al (2019) Neoadjuvant and adjuvant strategies for hepatocellular carcinoma. World J Gastroenterol 25:3704–3721PubMedPubMedCentral
3.
Zurück zum Zitat Bagante F, Spolverato G, Weiss M et al (2018) Assessment of lymphnode status in patients undergoing resection for intrahepatic cholangiocarcinoma: the new eighth edition AJCC Staging system. J Gastrointest Surg 24:2491–2501 Bagante F, Spolverato G, Weiss M et al (2018) Assessment of lymphnode status in patients undergoing resection for intrahepatic cholangiocarcinoma: the new eighth edition AJCC Staging system. J Gastrointest Surg 24:2491–2501
4.
Zurück zum Zitat Bagante F, Spolverato G, Weiss M et al (2018) Surgical management of intrahepatic cholangiocarcinoma in patients with cirrhosis: impact of lymphadenectomy on peri-operative outcomes. World J Surg 42:2551–2560PubMed Bagante F, Spolverato G, Weiss M et al (2018) Surgical management of intrahepatic cholangiocarcinoma in patients with cirrhosis: impact of lymphadenectomy on peri-operative outcomes. World J Surg 42:2551–2560PubMed
5.
Zurück zum Zitat Bartsch F, Paschold M, Baumgart J et al (2019) Surgical resection for recurrent intrahepatic cholangiocarcinoma. World J Surg 43:1105–1116PubMed Bartsch F, Paschold M, Baumgart J et al (2019) Surgical resection for recurrent intrahepatic cholangiocarcinoma. World J Surg 43:1105–1116PubMed
6.
Zurück zum Zitat Bartsch F, Tripke V, Baumgart J et al (2019) Extended resection of intrahepatic cholangiocarcinoma: a retrospective single-center cohort study. Int J Surg 67:62–69PubMed Bartsch F, Tripke V, Baumgart J et al (2019) Extended resection of intrahepatic cholangiocarcinoma: a retrospective single-center cohort study. Int J Surg 67:62–69PubMed
7.
Zurück zum Zitat Bhangui P, Allard MA, Vibert E et al (2016) Salvage versus primary liver transplantation for early hepatocellular carcinoma: do both strategies yield similar outcomes? Ann Surg 264:155–163PubMed Bhangui P, Allard MA, Vibert E et al (2016) Salvage versus primary liver transplantation for early hepatocellular carcinoma: do both strategies yield similar outcomes? Ann Surg 264:155–163PubMed
8.
Zurück zum Zitat Bridgewater J, Galle PR, Khan SA et al (2014) Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 60:1268–1289PubMed Bridgewater J, Galle PR, Khan SA et al (2014) Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 60:1268–1289PubMed
9.
Zurück zum Zitat Brierley J, Gospodarowicz M, Wittekind C (2017) International union against cancer, 8. Aufl. TNM Classification of Malignant Tumours. Wiley-Blackwell, Oxford Brierley J, Gospodarowicz M, Wittekind C (2017) International union against cancer, 8. Aufl. TNM Classification of Malignant Tumours. Wiley-Blackwell, Oxford
10.
Zurück zum Zitat Bruix J, Takayama T, Mazzaferro V et al (2015) Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3 randomized, double blind, placebo-controlled trial. Lancet Oncol 16:1344–1354PubMed Bruix J, Takayama T, Mazzaferro V et al (2015) Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3 randomized, double blind, placebo-controlled trial. Lancet Oncol 16:1344–1354PubMed
11.
Zurück zum Zitat Cherqui D, Laurent A, Mocellin N et al (2009) Liver resection for transplantable hepatocellular carcinoma:long-term survival and role of secondary liver transplantation. Ann Surg 250:738–746PubMed Cherqui D, Laurent A, Mocellin N et al (2009) Liver resection for transplantable hepatocellular carcinoma:long-term survival and role of secondary liver transplantation. Ann Surg 250:738–746PubMed
12.
Zurück zum Zitat Donadon M, Fontana A, Procopio F et al (2019) Dissecting the multinodular hepatocellular carcinoma subset:is there a survival benefit after hepatectomy? Updates Surg 71:57–66PubMed Donadon M, Fontana A, Procopio F et al (2019) Dissecting the multinodular hepatocellular carcinoma subset:is there a survival benefit after hepatectomy? Updates Surg 71:57–66PubMed
13.
Zurück zum Zitat Donadon M, Terrone A, Procopio F et al (2019) Is R1 vascular hepatectomy for hepatocellular carcinoma oncologically adequate? Analysis of 327 consecutive patients. Surgery 165:897–904PubMed Donadon M, Terrone A, Procopio F et al (2019) Is R1 vascular hepatectomy for hepatocellular carcinoma oncologically adequate? Analysis of 327 consecutive patients. Surgery 165:897–904PubMed
14.
Zurück zum Zitat Duvoux C, Roudot-Thoraval F, Decaens T et al (2012) Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology 143:986–994PubMed Duvoux C, Roudot-Thoraval F, Decaens T et al (2012) Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology 143:986–994PubMed
15.
Zurück zum Zitat El-Diwany R, Pawlik TM, Ejaz A (2019) Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am 28:587–599PubMed El-Diwany R, Pawlik TM, Ejaz A (2019) Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am 28:587–599PubMed
16.
Zurück zum Zitat European Association for the Study of the Liver (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236 European Association for the Study of the Liver (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236
17.
Zurück zum Zitat Fang JH, Zhou HC, Zhang C et al (2015) A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial-mesenchymal transition-independent manner. Hepatology 62:452–465PubMed Fang JH, Zhou HC, Zhang C et al (2015) A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial-mesenchymal transition-independent manner. Hepatology 62:452–465PubMed
18.
Zurück zum Zitat Greten TF, Malek NP, Schmidt S et al (2013) Diagnosis of and therapy for hepatocellular carcinoma. Z Gastroenterol 51:1269–1326PubMedPubMedCentral Greten TF, Malek NP, Schmidt S et al (2013) Diagnosis of and therapy for hepatocellular carcinoma. Z Gastroenterol 51:1269–1326PubMedPubMedCentral
19.
Zurück zum Zitat Heinrich S, Baumgart J, Mittler J et al (2016) Gefäßrekonstruktionen in der Leberchirurgie. Chirurg 87:100–107PubMed Heinrich S, Baumgart J, Mittler J et al (2016) Gefäßrekonstruktionen in der Leberchirurgie. Chirurg 87:100–107PubMed
20.
Zurück zum Zitat Bekanntgaben der Herausgeber: Bundesärztekammer (2019) Richtlinien zur Organtransplantation gem. § 16 TPG. Dtsch Arztebl 116(4):A-175 (B-151/C-151) Bekanntgaben der Herausgeber: Bundesärztekammer (2019) Richtlinien zur Organtransplantation gem. § 16 TPG. Dtsch Arztebl 116(4):A-175 (B-151/C-151)
21.
Zurück zum Zitat Imamura H, Matsuyama Y, Tanaka E et al (2003) Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38:200–207PubMed Imamura H, Matsuyama Y, Tanaka E et al (2003) Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38:200–207PubMed
22.
Zurück zum Zitat Isfordink CJ, Samim M, Braat M et al (2017) Portal vein ligation versus portal vein embolization for induction of hypertrophy of the future liver remnant: a systematic review and meta-analysis. Surg Oncol 26:257–267PubMed Isfordink CJ, Samim M, Braat M et al (2017) Portal vein ligation versus portal vein embolization for induction of hypertrophy of the future liver remnant: a systematic review and meta-analysis. Surg Oncol 26:257–267PubMed
23.
Zurück zum Zitat Lafaro KJ, Pawlik TM (2015) Fibrolamellar hepatocellular carcinoma: current clinical perspectives. J Hepatocell Carcinoma 2:151–157PubMedPubMedCentral Lafaro KJ, Pawlik TM (2015) Fibrolamellar hepatocellular carcinoma: current clinical perspectives. J Hepatocell Carcinoma 2:151–157PubMedPubMedCentral
24.
Zurück zum Zitat Lang H, de Santibanes E, Schlitt HJ et al (2019) 10th anniversary of ALPPS-lessons learned and quo vadis. Ann Surg 269:114–119PubMed Lang H, de Santibanes E, Schlitt HJ et al (2019) 10th anniversary of ALPPS-lessons learned and quo vadis. Ann Surg 269:114–119PubMed
25.
Zurück zum Zitat Lang H, Radtke A, Hindennach M et al (2005) Impact of virtual tumor resection and computer-assisted risk analysis on operation planning and intraoperative strategy in major hepatic resection. Arch Surg 140:629–638PubMed Lang H, Radtke A, Hindennach M et al (2005) Impact of virtual tumor resection and computer-assisted risk analysis on operation planning and intraoperative strategy in major hepatic resection. Arch Surg 140:629–638PubMed
26.
Zurück zum Zitat Lang H, Sotiropoulos GC, Sgourakis G et al (2009) Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients. J Am Coll Surg 208:218–228PubMed Lang H, Sotiropoulos GC, Sgourakis G et al (2009) Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients. J Am Coll Surg 208:218–228PubMed
27.
Zurück zum Zitat Lang H, Sotiropoulos GC, Brokalaki EI et al (2007) Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg 205:27–36PubMed Lang H, Sotiropoulos GC, Brokalaki EI et al (2007) Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. J Am Coll Surg 205:27–36PubMed
28.
Zurück zum Zitat Lerut JP, Orlando G, Adam R et al (2007) The place of liver transplantation in the treatment of hepatic epitheloid hemamngioendothelioma:report of the European liver transplant registry. Ann Surg 246:949–957PubMed Lerut JP, Orlando G, Adam R et al (2007) The place of liver transplantation in the treatment of hepatic epitheloid hemamngioendothelioma:report of the European liver transplant registry. Ann Surg 246:949–957PubMed
29.
Zurück zum Zitat LeRoy B, Gelli M, Pittau G et al (2018) Neoadjuvant chemothetapy for initially unresectable intrahepatic cholangiocarcinoma. Br J Surg 105:839–847 LeRoy B, Gelli M, Pittau G et al (2018) Neoadjuvant chemothetapy for initially unresectable intrahepatic cholangiocarcinoma. Br J Surg 105:839–847
30.
Zurück zum Zitat Lunsford KE, Javle M, Heyne K et al (2018) Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol 3:337–348PubMed Lunsford KE, Javle M, Heyne K et al (2018) Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol 3:337–348PubMed
31.
Zurück zum Zitat Mazzaferro V, Regalia E, Doci R et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699PubMed Mazzaferro V, Regalia E, Doci R et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699PubMed
32.
Zurück zum Zitat Mazzaferro V, Sposito C, Zhou J (2018) Metroticket 2.0 Model for analysis of competing risks of death after liver transplantation for Hepatocellular Carcinoma. Gastroenterology 154:128–139PubMed Mazzaferro V, Sposito C, Zhou J (2018) Metroticket 2.0 Model for analysis of competing risks of death after liver transplantation for Hepatocellular Carcinoma. Gastroenterology 154:128–139PubMed
33.
Zurück zum Zitat Mehrabi A, Kashfi A, Fonouni H et al (2006) Primary malignant hepatic epitheloid hemangioendothelioma. Cancer 107:2108–2121PubMed Mehrabi A, Kashfi A, Fonouni H et al (2006) Primary malignant hepatic epitheloid hemangioendothelioma. Cancer 107:2108–2121PubMed
34.
Zurück zum Zitat Mergental H, Adam R, Ericson BG et al (2012) Liver transplantation for unresectable hepatocellular carcinoma in normal livers. J Hepatol 57:297–305PubMed Mergental H, Adam R, Ericson BG et al (2012) Liver transplantation for unresectable hepatocellular carcinoma in normal livers. J Hepatol 57:297–305PubMed
35.
Zurück zum Zitat Pinheiro RS, Waisberg DR, Nacif LS et al (2017) Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure? Transpl Gastroenterol Hepatol 2:68 Pinheiro RS, Waisberg DR, Nacif LS et al (2017) Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure? Transpl Gastroenterol Hepatol 2:68
36.
Zurück zum Zitat Primrose JN, Fox R, Palmer DH et al (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomized, controlled, multicenter, phase 3 study. Lancet Oncol 20:663–673PubMed Primrose JN, Fox R, Palmer DH et al (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomized, controlled, multicenter, phase 3 study. Lancet Oncol 20:663–673PubMed
37.
Zurück zum Zitat Rubinstein MM, Kaubisch A, Kinkhabwala M et al (2017) Bridging therapy effectiveness in the treatment of hepatocellular carcinoma prior to orthotopic liver transplantation. J Gastrointest Oncol 8:1051–1055PubMedPubMedCentral Rubinstein MM, Kaubisch A, Kinkhabwala M et al (2017) Bridging therapy effectiveness in the treatment of hepatocellular carcinoma prior to orthotopic liver transplantation. J Gastrointest Oncol 8:1051–1055PubMedPubMedCentral
38.
Zurück zum Zitat Sapisochin G, Facciuto M, Rubbia-Brandt L et al (2016) Liver transplantation for “very early” intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology 64:1178–1188PubMed Sapisochin G, Facciuto M, Rubbia-Brandt L et al (2016) Liver transplantation for “very early” intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology 64:1178–1188PubMed
40.
Zurück zum Zitat Spolverato G, Kim Y, Alexandrescu S et al (2016) Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection. Ann Surg Oncol 23:235–243PubMed Spolverato G, Kim Y, Alexandrescu S et al (2016) Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection. Ann Surg Oncol 23:235–243PubMed
41.
Zurück zum Zitat Stockmann M, Lock JF, Riecke B et al (2009) Prediction of postoperative outcomeafter hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg 250:119–125PubMed Stockmann M, Lock JF, Riecke B et al (2009) Prediction of postoperative outcomeafter hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg 250:119–125PubMed
42.
Zurück zum Zitat Thomas RM, Aloia TA, Truty MJ et al (2014) Treatment sequencing strategy for hepatic epitheloid haemangioendothelioma. HPB 16:677–685PubMed Thomas RM, Aloia TA, Truty MJ et al (2014) Treatment sequencing strategy for hepatic epitheloid haemangioendothelioma. HPB 16:677–685PubMed
43.
Zurück zum Zitat Toso C, Meeberg G, Hernandez-Alejandro R (2015) Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. Hepatology 62:158–165PubMed Toso C, Meeberg G, Hernandez-Alejandro R (2015) Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. Hepatology 62:158–165PubMed
44.
Zurück zum Zitat Tripke V, Heinrich S, Huber T et al (2019) Surgical therapy of primary hepatic angiosarcoma. BMC Surg 19:5PubMedPubMedCentral Tripke V, Heinrich S, Huber T et al (2019) Surgical therapy of primary hepatic angiosarcoma. BMC Surg 19:5PubMedPubMedCentral
45.
Zurück zum Zitat Vigano L, Procopio F, Mimmo A et al (2018) Oncologic superiority of anatomic resection of hepatocellular carcinoma by ultrasound-guided compression of the portal tributaries compared with nonanatomic resection: An analysis of patients matched for tumor characteristics and liver function. Surgery 164:1006–1013PubMed Vigano L, Procopio F, Mimmo A et al (2018) Oncologic superiority of anatomic resection of hepatocellular carcinoma by ultrasound-guided compression of the portal tributaries compared with nonanatomic resection: An analysis of patients matched for tumor characteristics and liver function. Surgery 164:1006–1013PubMed
46.
Zurück zum Zitat Wang ZY, Chen QL, Sun LL et al (2019) Laparoscopic versus open major liver resection for hepatocellular carcinoma: systematic review and meta-analysis of comparative cohort studies. BMC Cancer 19:1047PubMedPubMedCentral Wang ZY, Chen QL, Sun LL et al (2019) Laparoscopic versus open major liver resection for hepatocellular carcinoma: systematic review and meta-analysis of comparative cohort studies. BMC Cancer 19:1047PubMedPubMedCentral
47.
Zurück zum Zitat Yamasaki S et al (2003) Intrahepatic cholangiocarcinoma:macroscopic type and stage classification. J Hepatobiliary Pancreat Surg 12:134–138 Yamasaki S et al (2003) Intrahepatic cholangiocarcinoma:macroscopic type and stage classification. J Hepatobiliary Pancreat Surg 12:134–138
48.
Zurück zum Zitat Yao FY (2008) Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant 8:1982–1989PubMed Yao FY (2008) Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant 8:1982–1989PubMed
49.
Zurück zum Zitat Zhang XF, Bagante F, Chakedis J et al (2017) Perioperative and longterm outcome for Intrahepatic cholangiocarcinoma: Impact of major versus minor hepatectomy. J Gastrointest Surg 21:1841–1850PubMed Zhang XF, Bagante F, Chakedis J et al (2017) Perioperative and longterm outcome for Intrahepatic cholangiocarcinoma: Impact of major versus minor hepatectomy. J Gastrointest Surg 21:1841–1850PubMed
50.
Zurück zum Zitat Zhu YP, Chen YM, Matro E et al (2015) Primary hepatic angiosarcoma: a report of two cases and literature review. World J Gastroenterol 21:6088–6096PubMedPubMedCentral Zhu YP, Chen YM, Matro E et al (2015) Primary hepatic angiosarcoma: a report of two cases and literature review. World J Gastroenterol 21:6088–6096PubMedPubMedCentral
Metadaten
Titel
Chirurgische Therapie bei Lebertumoren – Leberresektion und -transplantation
verfasst von
Prof. Dr. H. Lang, MA, MD, FACS
S. Heinrich
F. Bartsch
F. Hüttl
J. Baumgart
J. Mittler
Publikationsdatum
03.02.2020
Verlag
Springer Medizin
Erschienen in
Die Innere Medizin / Ausgabe 2/2020
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI
https://doi.org/10.1007/s00108-020-00754-8

Weitere Artikel der Ausgabe 2/2020

Die Innere Medizin 2/2020 Zur Ausgabe

Kongresse des BDI

Kongresse des BDI

Mitteilungen der DGIM

Mitteilungen der DGIM

Passend zum Thema

ANZEIGE

Synergien nutzen gegen Tumore

Lungen- und Magentumore können dank Immuntherapien deutlich besser behandelt werden. Dennoch kommt es trotzdem weiterhin häufig zum Krankheitsprogress. Welche Therapieoptionen sich in der Zweitlinie am besten eignen, haben wir für Sie zusammengefasst.

ANZEIGE

Darmkrebsreihenuntersuchungen zeigen EU-weit Erfolge

In Europa haben viele Länder dem Darmkrebs mit Hilfe von Früherkennungsprogrammen den Kampf angesagt. Es gibt einen deutlichen Zusammenhang zwischen Inzidenz und Mortalität von Darmkrebs und der Zeitspanne seit Einführung von Reihenuntersuchungen.

ANZEIGE

GI-Tumore und die Rolle von Angiogenesehemmern

Content Hub

Entdecken Sie mit praxisrelevanten Patientenfällen, kompakten Studieninhalten, informativen Experteninterviews und weiteren spannenden Inhalten, wie Sie den vielseitigen Herausforderungen bei GI-Tumoren begegnen können. Hier erfahren Sie mehr! PP-RB-DE-2009